https://orcid.org/0000-0002-3688-2514
References
- Crowther MA, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998;79(06):1116–1118.
- Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. The Lancet. 2000;356(9241):1551–1553.
- Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. Ann Intern Med. 2002;137(4):251.
- Baker P, Gleghorn A, Tripp T, et al. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol. 2006;133(3):331–336.
- Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115(1):145–149.
- Dandonneau JM. Lorsque les préparations intraveineuses empruntent la voie orale. Québec Pharm. 1995;42:256–258.
- Gunther KE, Conway G, Leibach L, et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10. Thromb Res. 2004;113(3-4):205–209.
- Shanbhag S, Dane KE, Streiff MB. “The 700-Dollar Vitamin”: the epidemic of synthetic cannabinoid-associated coagulopathy. a case study of excessive generic drug prices in the American Health Care System. Mayo Clin Proc. 2019;94(2):199–201.
- Afanasjeva J. Administration of injectable vitamin K orally. Hosp Pharm. 2017;52(9):645–649.
- Kelkar AH, Smith NA, Martial A, et al. An outbreak of synthetic Cannabinoid-Associated coagulopathy in Illinois. N Engl J Med. 2018;379(13):1216–1223.